Clinical Trial Update: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers [Phase 1]

View source ↗

Summary

Phase 1 study of cosibelimab (CK-301) as a single-agent therapy in adults with advanced cancers; the trial status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Malignant Mesothelioma
• Melanoma
• Merkel Cell Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• cosibelimab (cosibelimab)

Snippet

Sponsor: Checkpoint Therapeutics, Inc. | Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: ACTIVE_NOT_RECRUITING